- Company
- Avastin biosimilars occupy over 40% of Avastin mkt
- by Chon, Seung-Hyun Jul 3, 2024 05:51am
- Homegrown biosimilars are rapidly expanding their influence in the KRW 100 billion-a-year Avastin market. Biosimilars’ sales have increased to exceed 40% in less than 2 years. Samsung Bioepis' Onbevzi led the growth with sales close to the original drug. According to the market research firm IQVIA, the market size of bevacizumab anticancer d
- Company
- KOR, with 12 items, ranks '2nd' in FDA-approved biosimilars
- by Kim, Jin-Gu Jul 3, 2024 05:51am
- The U.S. Food and Drug Administration (FDA) has approved 56 biosimilars as of the first half of this year. Twelve of these were from Korean companies, ranking second after the United States. Until now, companies from the United States, South Korea, Germany, and Swiss dominated the U.S. biosimilar market. Recently, companies from India, Icela
- Company
- Eliquis generics will soon return to market
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- The patent for Eliquis (apixaban), a direct-acting oral anticoagulant (DOAC) worth KRW 80 billion a year, will expire in September. As such, generic versions of Eliquis, which were withdrawn from the market in 2021 due to the Supreme Court's reversed decision, will re-enter the market thereafter. The return of generics is expected to once
- Company
- New drug 'Aquipta' for migraine available for prescriptions
- by Eo, Yun-Ho Jul 3, 2024 05:50am
- The new drug 'Aquipta,' an oral migraine treatment, is becoming available in general hospitals in South Korea. According to industry sources, AbbVie Korea’s Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of the ‘Big 5’ tertiary general
- Company
- CSL Behring’s hemophilia B Tx Idelvion is reimbursed in KOR
- by Kang, Hye-Kyung Jul 3, 2024 05:50am
- CSL Behring Korea's hemophilia B treatment Idelvion (albutrepenonacog alfa,) will be reimbursed by Korea’s national health insurance starting in July for the treatment of adult and pediatric patients. Idelvion is approved for the control and routine prophylaxis of bleeding in adults and pediatric patients and for perioperative management
- Company
- Daewoong and LG Chem launch Humira biosimilar 'Xelenka'
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- Daewoong Pharmaceutical and LG Chem said on July 1st that they have launched 'Xelenka,' a Humira (adalimumab) biosimilar. Daewoong Pharmaceutical and LG Chem signed a distributer agreement for domestic sales earlier. Under the agreement, LG Chem will supply Xelenka to Daewoong Pharmaceutical, and Daewoong will handle domestic sales and
- Company
- Hugel signs distribution partnership agreement with Benev
- by Nho, Byung Chul Jul 2, 2024 05:49am
- The global total medical aesthetics company Hugel(Chair: Suk-yong Cha) will officially enter the U.S. market through a strategic partnership with the U.S.-based Benev Company. The company began discussions on a partnership to sell its botulinum toxin product ‘(Letybo, Korean brand name: Botulax)’ in the U.S. in August last year, and f
- Company
- PNH drug Voydeya is approved…new treatment option for PNH
- by Hwang, Byung-woo Jul 2, 2024 05:49am
- A new option for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) has been introduced in Korea with the approval of Voydeya (danicopan), a first-in-class oral factor D inhibitor. Voydeya is AstraZeneca Korea's PNH treatment that was approved by the Ministry of Food and Drug Safety (MFDS) on March 28th. Voydeya is a first-in
- Company
- GLP-1 uses↑…targets MASH, diabetes, and obesity
- by Son, Hyung-Min Jul 1, 2024 05:48am
- New drug candidates of the GLP-1 class target metabolic dysfunction-associated steatohepatitis (MASH) in addition to diabetes and obesity. Global pharmaceutical companies, such as Novo Nordisk, Eli Lily, Boehringer Ingelheim, and Korean pharmaceutical companies, including Dong-A ST and D&D pharmatech, are developing GLP-1 agents for the treat
- Company
- Companies to focus on developing trispecific antibodies
- by Son, Hyung-Min Jul 1, 2024 05:48am
- The pharmaceutical industry in South Korea and overseas has begun developing trispecific antibodies that bind three targets. Previously, these companies focused on bispecific antibodies, which can bind simultaneously to two different antigens or two antigenic epitopes on a single antigen. Crossing the blood-brain barrier (BBB) can increase th
